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background: In the CAPRIE trial, clopidogrel montotherapy was associated with a greater reduction in ischemic events compared with aspirin 
monotherapy in patients with atherosclerotic disease. The magnitude of such effects was higher among smokers compared with non-smokers. The 
effect of smoking on pharmacodynamic (PD) profiles of aspirin versus clopidogrel monotherapy has been poorly explored.
Methods: Sixty aspirin-treated (81mg/day) patients with atherosclerotic disease, classified as non, light and heavy smokers according to cotinine 
serum levels, were enrolled. Patients switched to clopidogrel (75mg/day) monotherapy for 7 days. PD assessments were performed before and after 
switch by Multiple Electrode Aggregometry with ASPI (arachidonic acid), ADP-PGE1 (adenosine diphosphate with prostaglandin E1), COLL (collagen) 
and TRAP (thrombin receptor-activating peptide).
results: On treatment platelet reactivity following ADP-PGE1 and TRAP stimuli was significantly lower among heavy smokers following switch to 
clopidogrel (Figure). A significant inverse effect was observed with ASPI, while neutral findings were shown with COLL stimuli (Figure).
 conclusions: In heavy smokers with atherosclerotic disease, clopidogrel is associated with enhanced platelet inhibitory effects, affecting 
purinergic and non-purinergic pathways, compared with aspirin. These PD findings may contribute to the enhanced relative ischemic benefit 
(“smoker’s paradox”) of clopidogrel among smokers.
